cafepharma’s detailpiece

And are they paid actual money or do they do it solely for the good feeling that comes from imparting clinical data to Dr’s? See story here

An interesting quote from last night on the GSK board addresses why the negative media publicity can have such a strong effect on product sales:
This poster has nailed it. You can talk science until you’re blue in the face. The study could be the worst POS ever designed. But once the public hears “Avandia kills […]

How to leverage a Viagra side effect here.

By now the news has pretty much reached everyone - a Cleveland Clinic study in the New England Journal of Medicine finds that diabetes drug Avandia causes increased cardiovascular risk in patients.  Although a GSK press release tries to reassure, the stock is dropping, and analysts are downgrading.
The GSK board on cafepharma was of course […]

Fifty-eight percent of pharma executives in a new PricewaterhouseCoopers survey think so.  China and India lead the list of countries where pharma firms are looking to expand.  Improvement in patent protection in Asian countries was cited as a leading reason for the increased interest in the area.
Please see this Reuters article for more details.

Help for facial wrinkles, migraines, and even excessive sweating and possibly cerebral palsy.  Now it may be indicated for urinary problems:
Allergan’s Botox could help urinary problems

Sepracor shares dropped 16% today after info posted on a US gov’t website caused some analysts to believe that Medicare payments would be reduced on their asthma drug Xopenex (Sepracor’s biggest product, accounting for over half of their revenues in Q1).
Details at Bloomberg.

Just yesterday, B&L announced that it was being bought out by private equity company Warburg Pincus.  Now it is announcing the formation of a new sales organization to focus on retinal products in the US.  This team ”will provide best-in-class sales support to surgeons for the company’s extensive portfolio of retina products.”
See details at PharmaLive.com.

Interesting recent thread on the Bristol-Myers board:

Pfizer co-promoted with Parke-Davis then took them all.
Pfizer co-promoted with Pharmacia then took some of them.
Pfizer co-promotes with us…will they take any of us?

And later in the thread:

Pfizer will have to make a major buy out of another company well before Lipitor goes off patent in 2010. Pfizer wants […]

With generic copies affecting big pharma’s drug sales, and not enough new drugs from their own research, companies such as Novartis and GSK are increasingly turning to licensing for new offerings.  Last year big pharma spent a record $23 billion buying smaller competitors or their drugs.  They are often willing to give up to 50% […]